Following the earlier announcement on the restructuring of its supply chain operating model, the board of GSK Consumer Nigeria Plc has approved the selection of Fidson Healthcare PLC as its contract manufacturing partner in Nigeria. With this decision Fidson Healthcare PLC will contract manufacture five (5) formulations (“Products”) for GSK Consumer Nigeria Plc. This decision was reached after a detailed and rigorous request for quotation (RFQ) process that involved a number of local manufacturers in Nigeria.
With this selection, and subject to the meeting of appropriate regulatory requirements, GSK would be transitioning the manufacturing of five (5) of its products to Fidson Healthcare Plc from Q3 2021. This decision establishes GSK as one of the leading healthcare multinational companies localising productions of its brands via local contract manufacturing.
Speaking on the choice of local contract manufacturing, Managing Director of GSK Consumer Nigeria Plc, Mr. Bhushan Akshikar said “Working with a local contract manufacturer for the supply of our products, where practical, will build local expertise, transfer technical knowledge and improve local production capacities in the country. We believe this decision will allow us to build a more sustainable commercial business, enabling us to continue our efforts in supporting access to our consumer health products, medicines and vaccines across Nigeria and West Africa”
Fidson’s MD/CEO, Dr. Fidelis Ayebae said “we are very excited about this collaboration with GSK Consumer Nigeria Plc. Future growth and success in the healthcare industry will be fostered on the right partnerships, and we could not have asked for better partners at this stage of our growth. This partnership justifies the investment made in our ultra-modern, cGMP-compliant factory and will certainly promote the transfer of technical knowhow and technology while improving access to quality medicines for peoples of the West African sub-region and beyond”
The contract manufacturing strategy adopted by GSK is in line with the industrialisation plan of the Nigerian government – the Nigerian Industrial Revolution Plan (NIRP), which is a bold plan to ensure Nigeria becomes the preferred pharmaceutical manufacturing hub in West Africa. It is also targeted at making the country one of the top two manufacturing hubs in West Africa and the preferred source for supplying low and medium-technology consumer and industrial goods domestically and regionally.
It is important to note that all changes communicated do not impact GSK’s broader commitments to Global Health in Nigeria and across Africa. GSK Nigeria will continue to be listed on the Nigerian Stock Exchange (NSE).
About GlaxoSmithKline Consumer Nigeria PLC
An affiliate of GlaxoSmithKline plc, GlaxoSmithKline Consumer Nigeria PLC (GSK Nigeria) is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
For further information, see www.gsk.com/ng
About Fidson Healthcare Plc.
Fidson Healthcare Nigeria Plc is a leading pharmaceutical manufacturing company in Nigeria. Founded in 1995 the company was listed on the floor of the Nigerian Stock Exchange, NSE to become a publicly quoted company in 2008.
For further information, see www.fidson.com
Enquiries (GSK Nigeria only):
Uchenna Uwechia Tel: +234 1 2711 000
Omongiade Ehighebolo Tel: +234 1 2711 000
Email: ng.investors@gsk.com
